Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × FED × Nivolumab × Clear all

Phase

Status

Sponsor Class

OTHER 421 INDUSTRY 89 NIH 32 NETWORK 7 OTHER_GOV 5 FED 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 3 enzalutamide 3 Abiraterone Acetate 3 apalutamide 2 Topotecan 2 Testosterone 2 Celecoxib 2 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2 talabostat 1 sargramostim 1 pasireotide 1 leucoselect phytosome 1 capivasertib 1 abiraterone 1 Tablets 1 Streptozocin 1 Rituximab 1 Radiosurgery 1 Pluvicto 1 PT-100 dipeptide 1 Nivolumab 1 Mitoxantrone 1 Mercaptopurine 1 Leuprolide 1 Itraconazole 1 Imipramine 1 Granulocyte-Macrophage Colony-Stimulating Factor 1 Folic Acid 1 Fecal Microbiota Transplantation 1 Etoposide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06275360 2026-03-02

RIVAL

VA Office of Research and Development

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon ⚡